29 June 2021 – Destiny Pharma to present at Shares & AJ Bell Webinar – 6th July 2021

Destiny Pharma plc

(“Destiny Pharma” or “the Company”)

Destiny Pharma to present at the Shares and AJ Bell Investor
Webinar on 06 July 2021

Brighton, United Kingdom – 29 June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that its Chief Executive Officer, Neil Clark, will provide a live presentation on the Company at the Shares and AJ Bell Investor Evening Webinar on Tuesday, 06 July at 6:00 pm BST.

The Shares and AJ Bell Investor Evening Webinar is an opportunity for existing and potential investors to receive a business update from senior executives of listed PLCs.

Attendees will have the opportunity to ask questions to the presenters via an online chat window during the webinar.

Shareholders and potential investors can register to join the webinar for free at:
https://www.sharesmagazine.co.uk/events/event/shares-investor-evening–webinar-060721

-ENDS-

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com

Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com

About Destiny Pharma plc
Destiny Pharma is a UK based, clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence, which is the leading cause of hospital acquired infection in the US, and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of postsurgical staphylococcal hospital infections including MRSA. It is also codeveloping
SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections, and has earlier grant funded XF research projects.

For further information on the company, please visit https://www.destinypharma.com